Nomura raises Ranbaxy to 'buy' on Sun takeover
Reuters Market Eye - Ranbaxy Laboratories (RANB.NS) gains 0.2 percent to 481 rupees after Nomura upgrades the stock to "buy" from "reduce" and raises its target price to 543 rupees from 321 rupees on the back of its takeover by Sun Pharmaceutical Industries (SUN.NS).
Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.
Ranbaxy shares are trading well above the Sun offer that valued the takeover target at 457 rupees apiece.
Sun is trading 0.1 percent higher at 637.30 rupees.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
The World Trade Organization failed on Thursday to reach a deal to standardise customs rules, which would have been the first global trade reform in two decades but was blocked by India's demands for concessions on agricultural stockpiling. Full Article
China PMIs jump to multi-month highs in July, add to view economy is steadying Full Article